Breaking News

Financial Report: Charles River Laboratories

By Kristin Brooks | February 12, 2014

PCS segment sales up 8% in the quarter

Charles River Laboratories
4Q Revenues: $289.2 million (+3%)

4Q Earnings: $19.1 million (+4%)

FY Revenues: $1.2 billion (+3%)

FY Earnings: $102.8 million (+6%)

Comments: Research Models and Services (RMS) segment sales were flat at $172.3 million in the quarter, and $707.1 million for the year, up 2%. Preclinical Services (PCS) segment sales were $117.0 million in the quarter, up 8%, led by demand from mid-tier biotechnology clients, as well as continued growth of global key accounts, and for the year sales were $458.4 million, up 6%.
blog comments powered by Disqus
  • CRO-Sponsor Partnerships

    CRO-Sponsor Partnerships

    Craig Morgan, Brand Development Director, goBalto Inc.||October 11, 2016
    10 tips for enabling better CRO and sponsor collaborations

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • The Search &  Rescue Mission for Data Integrity

    The Search & Rescue Mission for Data Integrity

    Mike Jovanis, Vice President of Vault QualityDocs, Veeva Systems||October 11, 2016
    Cloud technology is essential for success